Earnings per share (EPS) climbed to 1.08 cents in the 2HFY2021 from 0.91 cents a year ago on a fully diluted basis.
In 2HFY2021, revenue for the group inched up by 1.4% y-o-y to $31.9 million mainly due to higher revenue from its 60%-owned subsidiary CellVec, which surged 70.1% y-o-y.
The group’s increase in revenue was also attributable to the higher revenue from its oncology services segment.
These were partly offset by the decrease in revenue derived from the stem cell processing and storage services during the half-year period.
See also: Keppel Pacific Oak US REIT’s 1QFY2025 distributable income falls by 19.3% y-o-y to US$9.6 mil
As at end-December, cash and cash equivalents stood at $82.2 million.
The group has proposed a final dividend of 0.90 cents, which is 20% higher than the final dividend of 0.75 cents paid out in the year before.
The final dividend will be paid on May 11.
See also: Keppel DC REIT reports 1QFY2025 DPU of 2.503 cents, 14.2% higher y-o-y
Shares in TalkMed closed flat at 40 cents on Feb 15.
Photo: Stock image
